⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292291 | 0.94 | SLC6A2 (0.37) | — | |
| SCHEMBL823220 | 0.79 | MAPT (0.38) | — | |
| SCHEMBL27603861 | 0.79 | — | — | |
| Water SCHEMBL27872681 | 0.78 | MAPT (0.37) | — | |
| SCHEMBL11328514 | 0.75 | POLB (0.31) | — | |
| SCHEMBL2533234 | 0.74 | — | — | |
| SCHEMBL386334 | 0.74 | — | — | |
| SCHEMBL8122200 | 0.74 | — | — | |
| SCHEMBL28643823 | 0.74 | — | — | |
| SCHEMBL11328517 | 0.74 | MAPT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037872-A1 | N6 heterocyclic 5' modified adenosine derivatives | CV THERAPEUTICS, INC. | 2002-03-28 | — | — | US | claimed |
| US-6258793-B1 | MODIFYING CARDIAC ACTIVITY, MODIFYING ADIPOCYTE FUNCTION, TREATING CENTRAL NERVOUS SYSTEM DISORDERS, AND TREATING DIABETIC DISORDERS AND OBESITY IN MAMMALS | CV THERAPEUTICS, INC. | 2001-07-10 | — | — | US | claimed |
| WO-2001040245-A1 | N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| WO-2001040244-A1 | N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| EP-0217243-A2 | Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same | SUNTORY LIMITED (JP) | 1987-04-08 | — | — | EP | claimed |
| US-20020037872-A1 | N6 heterocyclic 5' modified adenosine derivatives | CV THERAPEUTICS, INC. | 2002-03-28 | — | — | US | disclosed |
| US-6258793-B1 | MODIFYING CARDIAC ACTIVITY, MODIFYING ADIPOCYTE FUNCTION, TREATING CENTRAL NERVOUS SYSTEM DISORDERS, AND TREATING DIABETIC DISORDERS AND OBESITY IN MAMMALS | CV THERAPEUTICS, INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2001040244-A1 | N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040245-A1 | N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| CN-1036064-C | Benzene derivatives having NGF production-promoting activity | SANKYO CO (JP) | 1997-10-08 | — | — | CN | disclosed |
| US-5643925-A | COGNITION ACTIVATORS AND NERVE GROWTH FACTORS | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5614521-A | NERVE GROWTH FACTOR | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0501656-B1 | New benzene derivatives having (NGF) production-promoting activity | SANKYO CO (JP) | 1997-01-22 | — | — | EP | disclosed |
| CN-1064273-A | The new NGF that has generates the active benzene derivative of promotion | SANKYO CO (JP) | 1992-09-09 | — | — | CN | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |